The filing is a routine update of the corporate deck — no new material catalyst. Monitor upcoming TILVANCE-301 interim ORR analysis and IOV-LUN-202 registrational data for NSCLC, which could be significant catalysts. Quarterly revenue growth trajectory supports the commercial thesis but is already priced into the analyst consensus (80% bullish).
Price Chart
Executive Summary
Iovance Biotherapeutics filed an 8-K with an updated corporate presentation used at healthcare conferences. The presentation highlights ~66% YoY revenue growth in Q2 2026, a ~$99M quarterly revenue >10% above guidance, ~56% gross margin from cost of sales, and ~$304M cash runway into 2H 2028. The filing is a routine business update with no material new events beyond the existing pipeline and commercial progress.
Key Facts
- 2Q26 revenue ~$99M, >10% above guidance, ~66% YoY growth
- Cash position ~$304M as of June 30, 2026, runway into 2H 2028
- ~56% gross margin from cost of sales in 2Q26, 50% YTD
- >95 authorized treatment centers in North America
- ~2,000 patients treated with commercial and clinical Iovance TIL products
- Lifileucel potential launch in 2L mNSCLC in 2H 2027 with FDA Fast Track Designation
- Phase 3 TILVANCE-301 trial for frontline advanced melanoma enrolling on track
- Phase 2 SARATOGA registrational trial for soft tissue sarcomas commenced in 2Q 2026
Financial Impact
No new material financial information beyond previously disclosed Q2 2026 revenue ~$99M and cash position ~$304M
Risk Factors
- Clinical trial results may not support regulatory approvals
- Commercial adoption of Amtagvi may not sustain current growth rates
- Cash runway only into 2H 2028 — may require future capital raises
- Competition from other cell therapies or immunotherapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-092145 |
| Document: tm2622463d1_8k.htm | 0001104659-26-092145 |
| Document: 0001104659-26-092145-index-headers.html | 0001104659-26-092145 |
| Document: 0001104659-26-092145-index.html | 0001104659-26-092145 |
| Document: 0001104659-26-092145.txt | 0001104659-26-092145 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $8.06 $10.64 | ▲ +32.01% | ▲ +30.70% | $14.24 (+76.67%) |
Aug 6, 2026 8w ago | 8-K | $6.34 $8.79 | ▲ +38.64% | ▲ +39.04% | $14.24 (+124.61%) |
Aug 6, 2026 8w ago | 8-K | $6.21 $8.70 | ▲ +40.10% | ▲ +39.50% | $14.24 (+129.31%) |
Jul 16, 2026 11w ago | Court Ruling | $4.66 $6.52 | ▼ −39.91% | ▼ −36.30% | $14.24 (−205.58%) |
Jul 2, 2026 13w ago | 8-K | $4.31 $4.69 | ▲ +8.82% | ▲ +9.23% | $14.24 (+230.39%) |
Jun 19, 2026 14w ago | Press Release | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 18, 2026 15w ago | S-3ASR | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 10, 2026 16w ago | 8-K | $3.96 $4.37 | ▲ +10.35% | ▲ +8.46% | $14.24 (+259.60%) |
May 22, 2026 18w ago | Press Release | $4.10 $4.34 | ▲ +5.87% | ▲ +7.81% | $14.24 (+247.32%) |
Apr 28, 2026 22w ago | DEFA14A | $3.31 $4.30 | ▲ +29.91% | ▲ +23.86% | $14.24 (+330.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access